Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis

Dysregulated hepatocyte lipid metabolism is a hallmark of hepatic lipotoxicity and contributes to the pathogenesis of nonalcoholic steatohepatitis (NASH). Acetyl CoA carboxylase (ACC) inhibitors decrease hepatocyte lipotoxicity by inhibiting de novo lipogenesis and concomitantly increasing fatty aci...

Descripción completa

Detalles Bibliográficos
Autores principales: Vijayakumar, Archana, Okesli‐Armlovich, Ayse, Wang, Ting, Olson, Isabel, Seung, Minji, Kusam, Saritha, Hollenback, David, Mahadevan, Sangeetha, Marchand, Bruno, Toteva, Maria, Breckenridge, David G., Trevaskis, James L., Bates, Jamie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426400/
https://www.ncbi.nlm.nih.gov/pubmed/35735253
http://dx.doi.org/10.1002/hep4.2011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426400/
https://www.ncbi.nlm.nih.gov/pubmed/35735253
http://dx.doi.org/10.1002/hep4.2011

Ejemplares similares